To Evaluate SSD8432/ Ritonavir in Adults With COVID-19

COVID-19 Patients Clinical Trial

Official title: Randomized, Double-blind, Phase Ib Clinical Trial to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetic of SSD8432/ Ritonavir Multiple Doses in Treatment of Adults With Asymptomatic Infection, Mild, and Common Type of COVID-19

Status Completed

Clinical Trial Summary

This is a randomized, double-blind, Phase 1b clinical trial to evaluate the safety, Pharmacodynamics, and Pharmacokinetic of SSD8432 combined with ritonavir tablets in adults with COVID-19.

Clinical Trial Description

This is a randomized, double-blinded, placebo-controlled, dose-climbing Phase Ib clinical trial, designed to evaluate the safety, pharmacodynamics, and pharmacokinetics of SSD8432/ ritonavir versus placebo in asymptomatic, mild, and common type adult COVID-19 subjects.

This clinical trial is planned to enroll 32 asymptomatic infected, mild or common type adult COVID-19 subjects, divided into 2 cohorts according to different doses of SSD8432:

Cohort 1: 16 subjects, 12 subjects will receive low-dose SSD8432/ ritonavir, and 4 subjects received placebo; Cohort 2: 16 subjects, 12 subjects will receive high-dose SSD8432/ ritonavir, and 4 subjects received placebo. ;

Related Conditions & MeSH terms

• COVID-19
• COVID-19 Patients

• NCT number: NCT05369676
• Study type: Interventional
• Source: Jiangsu Simcere Pharmaceutical Co., Ltd.
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: May 12, 2022
• Completion date: August 29, 2022